ZBIO Q1 2024 Earnings — Zenas BioPharma, Inc. Revenue & Financial Results | Market Cap Arena

ZBIOZenas BioPharma, Inc.

$1B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$23M

Operating Income

-$28M

Net Income

-$28M

EPS (Diluted)

$-0.73

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$947,000

Balance Sheet

Total Assets

$49M

Total Liabilities

$302M

Stockholders' Equity

-$252M

Cash & Equivalents

$37M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$23M	$0	—
Operating Income	-$28M	-$19M	-44.5%
Net Income	-$28M	-$19M	-45.6%